Altshuler David's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Jul 21, 2022
- Accession no.
- 0000899243-22-026486
- Filed
- Jul 21, 2022
- Trade date
- Jul 19, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.16M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Altshuler DavidCIK 0001550395 | Officer (EVP, Global Research and CSO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2022 | Common Stock | MOption exerciseAcquired | +10,427 | $187.53 | +$1,955,375.31 | 46,604 | Direct | |
| Jul 19, 2022 | Common Stock | MOption exerciseAcquired | +7,338 | $155.57 | +$1,141,572.66 | 53,942 | Direct | |
| Jul 19, 2022 | Common Stock | SSaleDisposed | −963 | $286.72F3,F4 | −$276,111.36 | 52,979 | Direct | |
| Jul 19, 2022 | Common Stock | SSaleDisposed | −4,561 | $287.83F3,F5 | −$1,312,792.63 | 48,418 | Direct | |
| Jul 19, 2022 | Common Stock | SSaleDisposed | −5,737 | $288.67F3,F6 | −$1,656,099.79 | 42,681 | Direct | |
| Jul 19, 2022 | Common Stock | SSaleDisposed | −6,604 | $289.48F3,F7 | −$1,911,725.92 | 36,077 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2022 | Common Stock | MOption exerciseDisposed | −10,427 | $0.00 | $0 | 3,911 | Direct | |
| Jul 19, 2022 | Common Stock | MOption exerciseDisposed | −7,338 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 4 transactions in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $288.67 (range $288.11 to $289.09).
Referenced by the price of 1 transaction in Table I.
- F7
Open market sales reported on this line occurred at a weighted average price of $289.48 (range $289.11 to $290.06).
Referenced by the price of 1 transaction in Table I.